Background Heart auscultation is a widely used and cost-effective clinical tool for detecting valvular heart disease (VHD), ...

Valvular heart diseases represent an underappreciated yet serious and growing public-health problem, particularly in the elderly, and this should be addressed with appropriate resources to improve ...

Clinical Study Open access Published: 21 July 2009 Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study T Wethal, M-B Lund, T Edvardsen, S D ...

Mild-to-moderate aortic and mitral regurgitation are frequently detected by echocardiogram in asymptomatic hypertensive patients. Our goal was to assess the prevalence and impact of mild-to ...

Boston Scientific has received expanded FDA approval for the use of its Watchman FLX and Watchman FLX Pro devices.

Valvular disease can happen when there is a problem with any of the 4 heart valves. Delaying treatment can worsen your health. So, stay proactive and improve your quality of life by seeking timely ...

The AI model was able to categorize precisely six selected types of valvular heart disease, with the Area Under the Curve, or AUC, ranging from 0.83 to 0.92. (AUC is a rating index that indicates ...

Treatment of valvular heart disease has made phenomenal strides over the past two decades, but these life-changing gains are not trickling down to everybody. A huge part of the problem is the lack of ...

The prevalence of valvular heart disease increased with age, from 21.2% for volunteers aged 60 to 64 years to 31.5% for those aged 70 to 74 years and 53.6% for those older than 85 years, according ...

The valvular heart disease comprises a significant reason for cardiovascular morbidity and mortality worldwide, where rheumatic heart disease (RHD) being the prevailing type of valvular heart ...

Jerome C.Robinson, M.D., Hugh B.Hull, M.D., and William J.Rappoport, M.D. Author Info & Affiliations Published September 23, 1965 N Engl J Med 1965;273: 680 - 683 DOI: 10.1056/NEJM196509232731303 ...

SÃO PAULO, BRAZIL — An analysis of a subset of patients in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial who had valvular heart ...